Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease

Inclusion Criteria:

1. Received vedolizumab (excluding comparator or placebo participants) duringparticipation in a qualifying vedolizumab study.
2. In the opinion of the investigator, the participant is continuing to derive benefitfrom vedolizumab and continued treatment with vedolizumab is desired because there isno other comparable product available or the participant may be expected to developworsening of disease if they were to modify treatment.
3. A male participant who is non-sterilized and sexually active with a female partner ofchildbearing potential agrees to use adequate contraception from signing of informedconsent throughout the duration of the study and for 18 weeks after last dose.
4. A female participant of childbearing potential who is sexually active with anon-sterilized male partner agrees to use routinely adequate contraception fromsigning of informed consent throughout the duration of the study and for 18 weeksafter last dose.

Exclusion Criteria:

1. For the participant's particular clinical scenario, vedolizumab is currently availableto the participant through commercial channels, including reimbursement.
2. Has any clinical condition or prior therapy that, in the opinion of the investigator,would make the participant unsuitable for the study or unable to comply with thedosing requirements or poses a risk to the participant being in the study.
3. If female, the participant is pregnant or lactating or intending to become pregnantbefore, during, or within 18 weeks after participating in this study; or intending todonate ova during such time period.
4. If male, the participant intends to donate sperm during the course of this study orfor 18 weeks thereafter.
5. Has received a live vaccine in the last 18 weeks or is in need of a live vaccineduring the study or up to 18 weeks after the last study dose.